XML 24 R12.htm IDEA: XBRL DOCUMENT

Patents

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Identifiable Intangible Assets

PATENTS

Acacia’s only identifiable intangible assets at June 30, 2017 and December 31, 2016 are patents and patent rights. Patent-related accumulated amortization totaled $369,129,000 and $358,043,000 as of June 30, 2017 and December 31, 2016, respectively.

Acacia’s patents have remaining estimated economic useful lives ranging from one to seven years. The weighted-average remaining estimated economic useful life of Acacia’s patents is approximately four years. The following table presents the scheduled annual aggregate amortization expense as of June 30, 2017 (in thousands):



For the years ending December 31,
Remainder of 2017	$	11,248
2018	21,256
2019	19,150
2020	6,707
2021	5,421
Thereafter	11,451
	$	75,233

Acacia recorded impairment of patent-related intangible asset charges of $40,165,000 for the six months ended

June 30, 2016, primarily comprised of the write-off of the remaining carrying value of our Adaptix portfolio. The impairment

charges were realized in the period due to a reduction in expected estimated future net cash flows and certain patent portfolios

that management determined it would no longer allocate future resources to in connection with the licensing and enforcement

of such portfolios, due primarily to the overall determination that future resources would be allocated to other licensing and

enforcement programs. The impairment charges consisted of the excess of the asset’s carrying value over its estimated fair

value.

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details